ClinicalTrials.gg
CompletedNCT06856538Updated Oct 8, 2026

Rhomboid Intercostal Sub Serratus Plane Block Versus Serratus Anterior Plane Block in Thoractomy

An interventional study of Bupivacain and Ultrasound in Thoracic and Pain, sponsored by Yasser S Mostafa, MD. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Yasser S Mostafa, MD · Not applicable, Interventional, and Prevention

How we know

Updated Oct 8, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies testing bupivacaine in Pain — 19 open to participants now, 19 under way, 3 of them phase 3. Bupivacaine · Pain.

Enrollment
108th of 146
40 · median 63
Started
2025
with 5 others
No phase
46 of 146
9 open now
Registered
135th of 146
by date

Among the 146 studies testing bupivacaine in Pain, this one is the 108th largest by enrollment, is one of 6 that started in 2025, is one of 46 with no phase, and was the 135th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 146 studies testing bupivacaine in Pain are open now, in 5 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies testing bupivacaine in Pain, or all of them as a file.
02

Study summary

The objective of the current study is to compare the efficacy of the analgesic effect of ultrasound-guided unilateral Rhomboid intercostal and sub serratus plane block (RISS) versus Serratus anterior plane block (SAPB) in Thoracotomy incision.

Read the detailed description

Open thoracotomy is commonly considered to be one of the most agonizing surgical operations. Pain following thoracotomy greatly impedes patient recovery and postoperative respiration. The pain experienced after a thoracotomy can originate from various factors, including the surgical incision, injury to the ribs and intercostal nerves, manipulation of the pleura and lung tissue, and the placement of a drainage tube.Recent advances in regional anesthesia techniques have aimed to provide more targeted and effective pain relief. Among these, ultrasound-guided fascial plane blocks, such as the rhomboid intercostal sub-serratus plane (RISS) block and the serratus anterior plane (SAP) block, have emerged as promising options. Both blocks target the thoracic nerves, but they differ in their anatomical approach and potential analgesic effects Postoperative pain was not only related to a comfortable recovery but also related to postoperative complications including pulmonary dysfunction, so the management of postoperative pain is an important part of the care of post operation.

Regional anesthesia techniques have been shown to have a good effect on postoperative analgesia and helps patients gain early recovery after operation.

Serratus anterior plane block (SAPB) is an easy, and safe method used for blockade of the sensory plane of the lateral cutaneous branch of the intercostal nerve (T2-T9).

The Serratus anterior plane block targets the lateral cutaneous branches of the thoracic intercostal nerves, which arise from the anterior rami of the thoracic spinal nerves and run in a neurovascular bundle immediately inferior to each rib. At the midaxillary line, the lateral cutaneous branches of the thoracic intercostal nerve traverse through the internal intercostal, external intercostal, and serratus anterior muscles innervating the musculature of the lateral thorax. These branches of the intercostal nerves travel through the two potential spaces described above.

The "Rhomboid intercostal and sub serratus plane block" (RISS) is a relatively newer block technique whose efficacy was documented in patients undergoing thoracic surgeries.

The RISS plane block involves the injection of local anesthetics into fascial planes, theoretically allowing for catheter placement to achieve continuous analgesia. Successful RISS plane blocks have been reported in various procedures, including lung transplantation, radical mastectomy, and nephrectomy, strongly suggesting favorable outcomes in postoperative pain relief.

In 2016, Elsharkawy et al. introduced a RA technique known as the rhomboid intercostal block (RIB). Rhomboid intercostal block involves injecting a local anesthetic into the upper intercostal muscle plane beneath the rhomboid muscles, providing analgesia to both the anterior and posterior thorax.Based on past studies, investigators found that RISS and SAPB are effectively decrease total opioid consumption, so investigators hypothesized one of them is the best.

Statistical analysis:

Statistical analysis will be conducted using IBM SPSS Statistics 22(IBM Corp., Armonk, NY, USA). The normal distribution of data will be assessed by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Mean and standard deviation will be used as descriptive statistics for normally distributed numerical variables, while median and interquartile range (25th to 75th percentiles) will be used as descriptive statistics for non-normally distributed numerical variables. In addition, Chi-square test or fisher exact test will be employed to test the significance between categorical variables as appropriate. Independent t test will be employed for numerical data that exhibited normal distribution, whereas the Mann-Whitney test will be used for numerical data that did not adhere to normal distribution. A significance level of p \< 0.05 will be deemed to be statistically significant.

03

Conditions studied

  • Thoracic
  • Pain

Browse trials for

Keywords

  • Rhomboid intercostal block
  • serratus anterior plane block
  • Thoracotomy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-70 years.
  • Patients scheduled for unilateral Thoracotomy.
  • (ASA) physical status I-III.
  • Patients who are candidates for general anesthesia.
  • No history of severe allergies to local anesthetics or other medications used during the procedure.

Exclusion criteria

Exclusion Criteria:

  • class ≥ IV patients.
  • obese ( ≥ 35) patients.
  • Patients with uncontrolled cardiovascular.
  • patients with neurological deficits, cardiopulmonary, hepatorenal , or metabolic diseases; anticoagulants; any drug allergies.
  • Patients with emergency surgeries or re-do surgeries.
  • Systemic infections or infections at the site of injection.
  • Psychiatric illnesses (schizophrenia, bipolar, uncontrolled anxiety or depression).
  • Narcotic dependency.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Group R

    A high- frequency linear ultrasound transducer will be placed longitudinally (in the sagittal plane) on the patient's back, just 2 cm medial to the medial scapular border. Then, the probe will be slightly rotated to obtain an oblique parasagittal plane. The following landmarks will be identified: the trapezius muscle, rhomboid major muscle, intercostal muscles, pleura, and lungs (from superficial to deep in order of appearance). The rhomboid major muscle will be distinguished at the level of the T6 and T7 vertebrae, below the trapezius muscle.

    Drug: Bupivacain · Device: Ultrasound

  • Active comparator
    Group S

    * The patient will be positioned laterally, and routine skin disinfection and draping will be completed. * Investigators also will use a linear ultrasound probe (Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID: 1385, Nile medical center, service@nilemed.net) for performing the block. * The fifth rib will be identified along the mid-axillary line to locate the deep serratus anterior muscle and the superficial latissimus dorsi muscle. * The needle will be inserted between the fifth and fourth ribs using a 22G (50 mm) puncture needle.

    Drug: Bupivacain · Device: Ultrasound

Interventions

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After the location will be confirmed through hydrodissection of 1 ml on the plane between the rhomboid major and the underlying intercostal muscles after confirming a negative aspiration via a a 22-gauge short bevel sonovisible needle (Spinocan, B. Braun Melsungen AG, Germany) using an in-plane technique then 10 ml of bupivacaine (concentration 0.25%) will be injected. and its spread will be manifested by the hydrodissection and widening of the plane visualized by ultrasound.

    Also known as: Marcaine 0.25%

  • DeviceUltrasound

    A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.

06

What researchers measure

Primary outcomes

  1. Total opioid consumption

    in microgram

    Time frame: 24 hours postoperatively.

Secondary outcomes

  1. Total intraoperative opioid consumption

    in microgram

    Time frame: from begining of operation till 5 minutes after extubation

  2. Visual analog pain score at rest

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: Immediately after the procedures

  3. Visual analog pain score at cough

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: Immediately after the procedures

  4. Visual analog pain score at rest

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: 1 hour postoperatively.

  5. Visual analog pain score at cough

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: 1 hour postoperatively.

  6. Visual analog pain score at rest

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: 3 hours postoperatively.

  7. Visual analog pain score at cough

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: 3 hours postoperatively.

  8. Visual analog pain score at rest

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: 6 hours postoperatively.

  9. Visual analog pain score at cough

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: 6 hours postoperatively.

  10. Visual analog pain score at rest

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: 12 hours postoperatively.

  11. Visual analog pain score at cough

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: 12 hours postoperatively.

  12. Visual analog pain score at rest

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: 24 hours postoperatively.

  13. Visual analog pain score at cough

    Ranging from 0 indicating no pain to 10 indicating extreme pain

    Time frame: 24 hours postoperatively.

  14. Time of first rescue analgesic

    in minutes

    Time frame: 5 minutes before first analgesic request

  15. Baseline Heart rate

    Beat / minute

    Time frame: 5 minutes before anesthesia

  16. Intraoperative Heart rate

    Beat / minute

    Time frame: every 30 minutes along operation

  17. Baseline mean arterial blood pressure

    mmHg

    Time frame: 5 minutes before anesthesia

  18. Intraoperative mean arterial blood pressure

    mmHg

    Time frame: every 30 minutes along operation

  19. Baseline oxygen saturation

    percentage with pulse oximetry

    Time frame: 5 minutes before anesthesia

  20. Intraoperative oxygen saturation

    percentage with pulse oximetry

    Time frame: every 30 minutes along operation

  21. Total length of stay in hospital

    in days

    Time frame: 1-2 days

  22. Patient satisfaction score

    5 degree Likeart scale where 1 Extremely satisfied to 5 Extremely not satisfied

    Time frame: 12 hours after end of operation and extubation

  23. Incidence of hematoma

    Yes or no

    Time frame: 30 minutes after nerve block

  24. Incidence of local anesthetic toxicity

    Yes or no

    Time frame: 30 minutes after nerve block

  25. Incidence of nausea

    Yes or no

    Time frame: 24 hours postoperative

  26. Incidence of vomiting

    Yes or no

    Time frame: 24 hours postoperative

  27. Ramsay sedation score

    From 1 to 5 (1 Awake; agitated or restless or both - 2 Awake; cooperative, oriented, and tranquil - 3 Awake but responds to commands only - 4 Asleep; brisk response to light glabellar tap or loud auditory stimulus - 5 Asleep; sluggish response to light glabellar tap or loud auditory stimulus) Asleep; no response to glabellar tap or loud auditory stimulus

    Time frame: 24 hours postoperative

Other outcomes

  1. Age

    in years

    Time frame: 5 minutes before entering operation department

  2. Sex

    Male of female

    Time frame: 5 minutes before entering operation department

07

Study locations

1 site
  • Fayoum University hospital
    El Fayoum Qesm, Faiyum Governorate 63514, Egypt
08

References and documents

Publications

  • Altiparmak B, Korkmaz Toker M, Uysal AI, Dere O, Ugur B. Evaluation of ultrasound-guided rhomboid intercostal nerve block for postoperative analgesia in breast cancer surgery: a prospective, randomized controlled trial. Reg Anesth Pain Med. 2020 Apr;45(4):277-282. doi: 10.1136/rapm-2019-101114. Epub 2020 Feb 19. PubMed 32079739 ↗
  • Longo F, Piliego C. Rhomboid intercostal and subserratus plane block for non-intubated video-assisted thoracoscopic surgery. J Clin Anesth. 2020 May;61:109612. doi: 10.1016/j.jclinane.2019.09.006. Epub 2019 Oct 24. No abstract available. PubMed 31668692 ↗
  • Hassan ME, Wadod MAA. Serratus anterior plane block and erector spinae plane block in postoperative analgesia in thoracotomy: A randomised controlled study. Indian J Anaesth. 2022 Feb;66(2):119-125. doi: 10.4103/ija.ija_257_21. Epub 2022 Feb 24. PubMed 35359482 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in May 2026, 15 months.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's 15 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Sep 2026 → May 2026 and completion Oct 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Mar 4, 2025
StartActual
Feb 1, 2025
Primary completionActual
May 1, 2026was Sep 2026
CompletionActual
Jun 1, 2026was Oct 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 8, 2026
Sites
1 site added, 1 site removed
Show site
  • Fayoum University hospital · El Fayoum Qesm, Egypt
Show 1 removed
  • Fayoum University hospital · Madīnat al Fayyūm, Egypt
Oct 8, 2026
Primary completion
Sep 1, 2026→May 1, 2026 (actual)
Oct 8, 2026
Study completion
Oct 1, 2026→Jun 1, 2026 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Fayoum University hospital · El Fayoum Qesm, Egypt
    Show 1 removed
    • Fayoum University hospital · Madīnat al Fayyūm, Egypt
    Primary completion Sep 1, 2026→May 1, 2026 (now actual)
    Study completion Oct 1, 2026→Jun 1, 2026 (now actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06856538
Lead sponsor
Yasser S Mostafa, MD
Responsible party
Yasser S Mostafa, MD (Lecturer, Fayoum University Hospital) — Sponsor-investigator
First posted
Mar 4, 2025
Start date
Feb 1, 2025
Primary completion
May 1, 2026
Completion
Jun 1, 2026
Last update
Oct 8, 2026

Study contacts

Mahdy A Abdelhady, MD
study chair · Fayoum University
Mohamed A Hamed, MD
principal investigator · Fayoum University
Mina M Sobhy, MD
study director · Fayoum University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion